Rhumbline Advisers Puma Biotechnology, Inc. Transaction History

Rhumbline Advisers

$113 Billion
Q2 2025

A detailed history of Rhumbline Advisers transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 60,611 shares of PBYI stock, worth $295,175. This represents 0.0% of its overall portfolio holdings.

Number of Shares

60,611

Previous 38,295 58.27%

Holding current value

$295,175

Previous $113,000 83.19%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 12, 2025	BUY	$2.74 - $3.72 $61,145 - $83,015	22,316 Added 58.27%	60,611 $207,000
Q1 2025 Apr 08, 2025	BUY	$2.76 - $3.88 $11 - $15	4 Added 0.01%	38,295 $120,000
Q4 2024 May 29, 2025	SELL	$2.42 - $3.39 $9 - $13	-4 Reduced 0.01%	38,291 $116,000
Q4 2024 Jan 30, 2025	SELL	$2.42 - $3.39 $20,175 - $28,262	-8,337 Reduced 17.88%	38,291 $116,000
Q3 2024 Nov 12, 2024	SELL	$2.25 - $4.03 $8,194 - $14,677	-3,642 Reduced 7.24%	46,628 $118,000
Q2 2024 Aug 01, 2024	BUY	$2.92 - $5.83 $140,697 - $280,912	48,184 Added 2309.88%	50,270 $163,000
Q2 2023 Aug 08, 2023	BUY	$2.6 - $3.58 $5,423 - $7,467	2,086 New	2,086 $7,000
Q2 2022 Aug 11, 2022	SELL	$1.64 - $3.3 $63,590 - $127,957	-38,775 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$2.13 - $3.24 $8 - $12	4 Added 0.01%	38,775 $112,000
Q4 2021 Feb 10, 2022	SELL	$2.85 - $6.58 $2,388 - $5,514	-838 Reduced 2.12%	38,771 $118,000
Q3 2021 Nov 12, 2021	BUY	$6.63 - $9.39 $3,765 - $5,333	568 Added 1.45%	39,609 $278,000
Q2 2021 Aug 05, 2021	SELL	$8.98 - $11.6 $21,983 - $28,396	-2,448 Reduced 5.9%	39,041 $358,000
Q1 2021 May 06, 2021	SELL	$9.38 - $13.63 $35,456 - $51,521	-3,780 Reduced 8.35%	41,489 $403,000
Q4 2020 Feb 10, 2021	BUY	$7.78 - $12.13 $25,362 - $39,543	3,260 Added 7.76%	45,269 $464,000
Q3 2020 Nov 12, 2020	SELL	$9.5 - $11.14 $67,089 - $78,670	-7,062 Reduced 14.39%	42,009 $424,000
Q2 2020 Aug 13, 2020	BUY	$7.01 - $13.24 $51,173 - $96,652	7,300 Added 17.48%	49,071 $512,000
Q1 2020 May 06, 2020	BUY	$6.28 - $14.57 $2,191 - $5,084	349 Added 0.84%	41,771 $353,000
Q4 2019 Feb 05, 2020	BUY	$6.5 - $10.73 $5,804 - $9,581	893 Added 2.2%	41,422 $362,000
Q3 2019 Oct 23, 2019	SELL	$8.75 - $12.85 $2,117 - $3,109	-242 Reduced 0.59%	40,529 $436,000
Q2 2019 Aug 14, 2019	BUY	$12.3 - $35.76 $25,411 - $73,880	2,066 Added 5.34%	40,771 $518,000
Q1 2019 May 01, 2019	SELL	$20.77 - $42.37 $4,839 - $9,872	-233 Reduced 0.6%	38,705 $1.5 Million
Q4 2018 Jan 31, 2019	BUY	$20.07 - $46.7 $248,566 - $578,379	12,385 Added 46.64%	38,938 $792,000
Q3 2018 Nov 07, 2018	SELL	$41.2 - $59.85 $71,729 - $104,198	-1,741 Reduced 6.15%	26,553 $1.22 Million
Q2 2018 Aug 06, 2018	BUY	$48.3 - $68.25 $6,423 - $9,077	133 Added 0.47%	28,294 $1.67 Million
Q1 2018 May 02, 2018	SELL	$59.7 - $99.25 $53,371 - $88,729	-894 Reduced 3.08%	28,161 $1.92 Million
Q4 2017 Feb 09, 2018	SELL	$93.85 - $132.45 $538,605 - $760,130	-5,739 Reduced 16.49%	29,055 $2.87 Million
Q3 2017 Nov 06, 2017	BUY	$72.0 - $119.75 $2.51 Million - $4.17 Million	34,794	34,794 $4.17 Million

Others Institutions Holding PBYI

# of Institutions

124

Shares Held

33.3M

Call Options Held

68.2K

Put Options Held

View Full List

About PUMA BIOTECHNOLOGY, INC.

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $222M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

More about PBYI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Puma Biotechnology, Inc. Transaction History